Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas.
| Condition | Intervention |
|---|---|
|
Chordoma Desmoid Tumor Sarcoma |
Genetic: DNA analysis Genetic: microarray analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis Other: mass spectrometry |
| Study Type: | Observational |
| Official Title: | Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) |
- Frequency of individual mutated genes in patients with NRSTS [ Designated as safety issue: No ]
- Genetic changes that are most common and likely to have the greatest therapeutic impact [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | March 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To determine the frequency with which actionable mutations are found in archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry (MS) analysis of tumor-derived deoxyribonucleic acid (DNA).
OUTLINE: Archived DNA tissue samples are analyzed for frequency of genetic mutations, including single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
Eligibility| Ages Eligible for Study: | up to 30 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA
- Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS
Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:
- COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol
- COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Peter C. Adamson, Children's Oncology Group - Group Chair Office |
| ClinicalTrials.gov Identifier: | NCT01567046 History of Changes |
| Other Study ID Numbers: | CDR0000729355, COG-ARST12B5 |
| Study First Received: | March 27, 2012 |
| Last Updated: | March 31, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
childhood epithelioid sarcoma childhood alveolar soft-part sarcoma childhood angiosarcoma childhood fibrosarcoma childhood leiomyosarcoma childhood liposarcoma childhood neurofibrosarcoma childhood synovial sarcoma |
metastatic childhood soft tissue sarcoma nonmetastatic childhood soft tissue sarcoma recurrent childhood soft tissue sarcoma chordoma childhood desmoplastic small round cell tumor desmoid tumor childhood malignant mesenchymoma |
Additional relevant MeSH terms:
|
Chordoma Fibromatosis, Aggressive Sarcoma Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms Fibroma Neoplasms, Fibrous Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue |
ClinicalTrials.gov processed this record on June 18, 2013